Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bortezomib + Daratumumab + Lenalidomide + Teclistamab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Daratumumab||Darzalex||JNJ-54767414||CD38 Antibody 13||Darzalex (Daratumumab) is a human antibody against CD38 that induces antibody-dependent cell-mediated cytotoxicity and complement-mediated cytotoxicity against CD38-positive tumor cells (PMID: 30546360). Darzalex (Daratumumab) is FDA approved for multiple myeloma patients as a monotherapy or in combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, or with bortezomib, melphalan, and prednisone, or with pomalidomide and dexamethasone, or with bortezomib, thalidomide and dexamethasone (FDA.gov).|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Teclistamab||JNJ-64007957|BCMAxCD3|JNJ 64007957|JNJ64007957||CD3 Antibody 55||Teclistamab (JNJ-64007957) is a bispecific antibody that targets CD3 and BCMA, potentially resulting in increased immune response against BCMA-expressing tumor cells (Blood Dec 2016, 128 (22) 5668).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04722146||Phase I||Nirogacestat + Teclistamab Daratumumab + Pomalidomide + Teclistamab Bortezomib + Daratumumab + Lenalidomide + Teclistamab||A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma||Recruiting||USA | FRA | BEL||2|